GENETIC ANALYSIS NK -60 (8V8) - Total Liabilities
Based on the latest financial reports, GENETIC ANALYSIS NK -60 (8V8) has total liabilities worth €23.93 Million EUR (≈ $27.97 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See 8V8 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
GENETIC ANALYSIS NK -60 - Total Liabilities Trend (2021–2025)
This chart illustrates how GENETIC ANALYSIS NK -60's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see GENETIC ANALYSIS NK -60 total assets.
GENETIC ANALYSIS NK -60 Competitors by Total Liabilities
The table below lists competitors of GENETIC ANALYSIS NK -60 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CDN Maverick Capital Corp.
F:338B
|
Germany | €349.51K |
|
Global Battery Metals Ltd
V:GBML
|
Canada | CA$1.03 Million |
|
ILYA Co. Ltd
KQ:058450
|
Korea | ₩18.36 Billion |
|
Invion Ltd
AU:IVX
|
Australia | AU$1.24 Million |
|
Photocat AS
ST:PCAT
|
Sweden | Skr11.83 Million |
|
Inventronics Ltd
V:IVX
|
Canada | CA$3.11 Million |
|
Kestrel Gold Inc
V:KGC
|
Canada | CA$35.81K |
|
Laxmi Cotspin Limited
NSE:LAXMICOT
|
India | Rs531.88 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down GENETIC ANALYSIS NK -60's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 8V8 net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GENETIC ANALYSIS NK -60's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GENETIC ANALYSIS NK -60 (2021–2025)
The table below shows the annual total liabilities of GENETIC ANALYSIS NK -60 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €25.37 Million ≈ $29.66 Million |
+27.57% |
| 2024-12-31 | €19.88 Million ≈ $23.25 Million |
-7.48% |
| 2023-12-31 | €21.49 Million ≈ $25.13 Million |
+5.95% |
| 2022-12-31 | €20.28 Million ≈ $23.71 Million |
+77.93% |
| 2021-12-31 | €11.40 Million ≈ $13.33 Million |
-- |
About GENETIC ANALYSIS NK -60
Genetic Analysis AS, a science-based diagnostic company, engages in the research, development, manufacturing, and sale of diagnostic test solutions for human microbiome in the United States, Europe, and internationally. The company offers GA-map MHI Gut Health Test, a microbiome-based diagnostic test for antibiotic-induced microbiome imbalances; GA-map Dysbiosis Test, a diagnostic microbiome test… Read more